Vanguard Global Advisers’s Royalty Pharma RPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$15.3M Buy
262,730
+32,253
+14% +$1.9M 0.01% 587
2026
Q2
$12.9M Sell
230,477
-8,512
-4% -$443K 0.01% 600
2026
Q1
$11.5M Buy
+238,989
New +$10.5M 0.01% 599

Other funds holding RPRX

Vanguard Global Advisers's RPRX Position: Q3 2026 in Review

Vanguard Global Advisers increased its Royalty Pharma (RPRX) stake by 14% in Q3 2026, buying an estimated $1.9M and bringing the position to 262,730 shares worth $15.3M. The position accounts for 0.01% of the portfolio, ranked #587.

Vanguard Global Advisers first reported a position in RPRX in Q1 2026 and has held it in 3 quarters since. 573 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

  • Vanguard Global Advisers held 262,730 shares of Royalty Pharma worth $15.3M as of Q3 2026.
  • Vanguard Global Advisers bought 32,253 Royalty Pharma shares in Q3 2026, an estimated $1.9M.
  • Royalty Pharma made up 0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #587 holding.
  • Vanguard Global Advisers first reported a position in Royalty Pharma in Q1 2026 and has held it in 3 quarters since.
  • 573 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.